Psychedelics are a tool. An important one, but a tool, not a cure, and not for everyone.
What makes psychedelic-assisted therapy different from conventional pharmacology is not the molecule. It is the paradigm. Integration, preparation, education, and the therapeutic relationship are inseparable from the outcome. Strip those away and you have a drug. Keep them and you have a genuinely different approach to healing.
Our healthcare system is drug-centric. It has been for decades. Psychedelic-assisted therapy, done responsibly, points toward something else: a model oriented around the whole person, the context of suffering, and the conditions that allow people to actually recover rather than manage symptoms indefinitely.
I was trained as a physician scientist in an era when what was best for the patient came first. Not cost containment. Not guidelines designed around liability. The patient. That orientation never left me, and it shapes everything about how I think this work should be done.
I will not draw conclusions from small samples or short timeframes. What I have seen in clinical contexts is promising enough to take seriously and complex enough to demand rigor. We need longitudinal data, careful variable tracking, and honest outcome measurement before we know what we actually have.
Commercial development of psychedelics will reach some people. That is not nothing. But a system where access depends entirely on what you can afford, or which company holds the patent, is not the system I am working to build. The path I am interested in is equitable, evidence-based, and designed around long-term healing, not the next drug cycle.
This is not an argument against commercial development. It is an argument for building something alongside it that serves everyone else.
I approach this work with heartfelt gratitude and unyielding optimism. The science is real. The need is urgent. And if we build this right, we leave the world just a little brighter than we found it.